Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 960.00M | 1.37B | 1.82B | 1.80B | 901.00M |
| Total Depreciation and Amortization | 1.17B | 1.23B | 1.23B | 1.23B | 1.22B |
| Total Amortization of Deferred Charges | 280.00M | -- | -- | -- | 292.00M |
| Total Other Non-Cash Items | -177.00M | -383.00M | -338.00M | -143.00M | -316.00M |
| Change in Net Operating Assets | 150.00M | 897.00M | -989.00M | 242.00M | 299.00M |
| Cash from Operations | 2.38B | 3.11B | 1.72B | 3.13B | 2.40B |
| Capital Expenditure | -525.00M | -319.00M | -270.00M | -247.00M | -372.00M |
| Sale of Property, Plant, and Equipment | 1.00M | 5.00M | 1.00M | 125.00M | 265.00M |
| Cash Acquisitions | -216.00M | -273.00M | -184.00M | -426.00M | -168.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -337.00M | -634.00M | -67.00M | -698.00M | 26.00M |
| Cash from Investing | -1.08B | -1.22B | -520.00M | -1.25B | -249.00M |
| Total Debt Issued | 51.00M | 38.00M | -35.00M | 3.92B | -304.00M |
| Total Debt Repaid | -361.00M | -1.31B | -1.47B | -2.07B | -72.00M |
| Issuance of Common Stock | 21.00M | 4.00M | 4.00M | 4.00M | 18.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.00M | -1.41B | -22.00M | -3.05B | 0.00 |
| Other Financing Activities | 0.00 | -46.00M | 0.00 | -840.00M | 0.00 |
| Cash from Financing | -291.00M | -2.73B | -1.52B | -2.03B | -358.00M |
| Foreign Exchange rate Adjustments | 6.00M | -19.00M | -36.00M | -11.00M | 6.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.02B | -852.00M | -357.00M | -155.00M | 1.80B |